Court Extends Restraining Order Against Ivax Diabetes Drug

Law360, New York (November 14, 2003, 12:00 AM EST) -- A U.S. District Court judge in Washington, D.C., extended a temporary restraining order that removed from the market Ivax's metformin extended release product, a generic version of Bristol-Myers Squibb's (BMS's) Type 2 diabetes drug Glucophage XR, Drug Industry Daily reported.

The court is considering arguments over which of two generic firms, Alpharma subsidiary Purepac or Ivax, will be given 180 days of market exclusivity on the product. The court has delayed ruling on the matter, and no further court dates have been scheduled, according to Drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.